No price history available.
Key financial summary
Financials in JPY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | 2027E | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | ¥m | 3,253,122 | 3,211,173 | 3,290,921 | 3,360,008 | 3,558,732 | 3,671,328 | 3,817,354 | N/A | N/A |
| Operating profit | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | ¥m | 37,969 | 23,927 | 29,424 | 38,806 | 41,475 | 40,280 | 42,535 | N/A | N/A |
| EPS reported | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in JPY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | 2027E | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Value | ||||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | ||||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | ||||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | ||||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Medipal Holdings Corporation, a Tokyo, Japan-based company founded in 1898, primarily specializes in the wholesale distribution of prescription pharmaceuticals throughout Japan. The firm procures a broad spectrum of healthcare products, including medical equipment, materials, and clinical diagnostic reagents, utilized across diagnostics, testing, treatment, and administration, often from the pre-symptomatic stage. It also offers contract-based post-marketing surveillance (PMS) services to manufacturers and strategically invests in products like orphan drugs. Beyond pharmaceuticals, Medipal Holdings diversifies its wholesale activities to encompass cosmetics, daily necessities, and over-the-counter medications. Its extensive product portfolio further includes animal health products for companion animals, raw materials for food processing in the agricultural, fisheries, and livestock sectors, along with livestock feed additives, various seasonings, veterinary medical equipment, packaging materials, and industrial chemicals. The company also provides a comprehensive suite of specialized services. These include conducting contract epidemiological and clinical studies, creating computerized databases for medical supplies and master product data for healthcare facilities, and offering health insurance claims reviews, medical coding dispatch, outsourcing, and remote education. Medipal's operations extend to life and non-life insurance agency services, cleaning management, the full management and operation of distribution centers, commissioned delivery, and worker dispatch. Additionally, it handles the planning, management, administration, and product/service development for its branded Class A health dispensing pharmacies. Serving an expansive client base, Medipal Holdings partners with hospitals, clinics, dispensing pharmacies, drugstores, home centers, convenience stores, supermarkets, discount stores, animal hospitals, livestock and fishery businesses, and processed food manufacturers. The company adopted its current name, Medipal Holdings Corporation in October 2009, having previously operated as Mediceo Paltac Holdings Co., Ltd.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
MediPal Holdings Corporation (7459.T)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Medipal Holdings Corporation, a Tokyo, Japan-based company founded in 1898, primarily specializes in the wholesale distribution of prescription pharmaceuticals throughout Japan. The firm procures a broad spectrum of healthcare products, including medical equipment, materials, and clinical diagnostic reagents, utilized across diagnostics, testing, treatment, and administration, often from the pre-symptomatic stage. It also offers contract-based post-marketing surveillance (PMS) services to manufacturers and strategically invests in products like orphan drugs. Beyond pharmaceuticals, Medipal Holdings diversifies its wholesale activities to encompass cosmetics, daily necessities, and over-the-counter medications. Its extensive product portfolio further includes animal health products for companion animals, raw materials for food processing in the agricultural, fisheries, and livestock sectors, along with livestock feed additives, various seasonings, veterinary medical equipment, packaging materials, and industrial chemicals. The company also provides a comprehensive suite of specialized services. These include conducting contract epidemiological and clinical studies, creating computerized databases for medical supplies and master product data for healthcare facilities, and offering health insurance claims reviews, medical coding dispatch, outsourcing, and remote education. Medipal's operations extend to life and non-life insurance agency services, cleaning management, the full management and operation of distribution centers, commissioned delivery, and worker dispatch. Additionally, it handles the planning, management, administration, and product/service development for its branded Class A health dispensing pharmacies. Serving an expansive client base, Medipal Holdings partners with hospitals, clinics, dispensing pharmacies, drugstores, home centers, convenience stores, supermarkets, discount stores, animal hospitals, livestock and fishery businesses, and processed food manufacturers. The company adopted its current name, Medipal Holdings Corporation in October 2009, having previously operated as Mediceo Paltac Holdings Co., Ltd.
